

Title (en)  
MALIGNANT NEOPLASIS TREATMENT USING PD-1 ANTIBODY COMBINATION

Title (de)  
BEHANDLUNG MALIGNER NEOPLASIS MIT PD-1-ANTIKÖRPERKOMBINATION

Title (fr)  
TRAITEMENT DE NÉOPLASIES MALIGNES À L'AIDE D'UNE COMBINAISON D'ANTICORPS ANTI-PD-1

Publication  
**EP 4319736 A1 20240214 (EN)**

Application  
**EP 22785065 A 20220408**

Priority  
• RU 2021109765 A 20210408  
• RU 2022050122 W 20220408

Abstract (en)  
[origin: WO2022216184A1] The present invention relates to the use of antibody to PD-1, in particular prolgolimab, in combination with at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin, for treating a malignant neoplasm in a subject in need thereof, and to the use of the antibody to PD-1 prolgolimab in combination with antibody to VEGF, in particular bevacizumab, and at least one chemotherapeutic agent, in particular paclitaxel, carboplatin, or cisplatin, for treating a malignant neoplasm in a subject in need thereof. The present invention further relates to a method for treating a malignant neoplasm in a subject in need thereof, comprising administering a therapeutically effective amount of antibody to PD-1, in particular prolgolimab, in combination with at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin, and to a method for treating a malignant neoplasm in a subject in need thereof, comprising administering a therapeutically effective amount of the antibody to PD-1 prolgolimab in combination with antibody to VEGF, in particular bevacizumab, and at least one chemotherapeutic agent, in particular paclitaxel, carboplatin or cisplatin.

IPC 8 full level  
**A61K 31/282** (2006.01); **A61K 31/337** (2006.01); **A61K 39/395** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)  
**A61K 31/337** (2013.01); **A61K 31/555** (2013.01); **A61K 33/243** (2019.01); **A61K 39/3955** (2013.01); **A61K 45/06** (2013.01); **A61P 35/00** (2018.01); **C07K 16/22** (2013.01); **C07K 16/2818** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/507** (2013.01); **A61K 2039/545** (2013.01)

C-Set (source: EP)  
1. **A61K 39/3955 + A61K 2300/00**  
2. **A61K 33/243 + A61K 2300/00**  
3. **A61K 31/337 + A61K 2300/00**  
4. **A61K 31/555 + A61K 2300/00**

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

Designated validation state (EPC)  
KH MA MD TN

DOCDB simple family (publication)  
**WO 2022216184 A1 20221013**; AR 125322 A1 20230705; BR 112023020856 A2 20240206; CL 2023003012 A1 20240412; CN 117500493 A 20240202; CO 2023013510 A2 20231110; EC SP23076237 A 20240131; EP 4319736 A1 20240214; MA 62924 A1 20240329; MX 2023011952 A 20231109; TW 202304511 A 20230201; UY 39724 A 20221031

DOCDB simple family (application)  
**RU 2022050122 W 20220408**; AR P220100896 A 20220408; BR 112023020856 A 20220408; CL 2023003012 A 20231006; CN 202280027483 A 20220408; CO 2023013510 A 20231012; EC DI202376237 A 20231006; EP 22785065 A 20220408; MA 62924 A 20220408; MX 2023011952 A 20220408; TW 111113464 A 20220408; UY 39724 A 20220408